You are here

Our science / Clinical Trials / Find a Trial / NCT02001181

Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema)

Back to Search Print Save as PDF Bookmark Trial

NCT02001181

Last updated on April 3, 2020
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
SKiN Centre for Dermatology
Peterborough, Ontario, K9J 1Z2 Canada
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Atopic Dermatitis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-60 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Have a clinical diagnosis of atopic dermatitis (also known as atopic eczema) for at
least 6 months prior to Day 1 that has been clinically stable for at least 1 month
prior to Day 1 and is confirmed to be atopic dermatitis according to the criteria of
Hanifin and Rajka.

- Have a PGA score of 2 (mild) or 3 (moderate) at Day 1.

- Have atopic dermatitis on the head (including face, but excluding hair bearing
scalp), neck, trunk (excluding groin and genitals), or limbs including palms and
soles covering at least 2% of total body surface area (BSA) and up to and including
20% of total BSA at Day 1. At least 2% of the total BSA will need to be on the head
(including face, but excluding hair bearing scalp), neck, trunk (excluding groin and
genitals), or limbs (excluding palms and soles).

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Evidence of certain skin conditions/infections at baseline

- Currently have atopic dermatitis on groin, genitals, palm or soles

- Have certain laboratory abnormalities at baseline

- Females who are pregnant, breastfeeding, or are of childbearing potential not using
highly effective contraception

NCT02001181
Pfizer
Completed
Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema)

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search

Based on your search, you may also be interested in

Atopic Dermatitis
A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic Dermatitis
NCT04040192
All Genders
2+
Years
Multiple Sites
Atopic Dermatitis
Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
NCT03422822
All Genders
12+
Years
Multiple Sites
Atopic Dermatitis
JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis
NCT03796676
All Genders
12+
Years
Multiple Sites
Atopic Dermatitis
Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis
NCT03915496
All Genders
18+
Years
Multiple Sites
Descriptive Information
Brief Title  ICMJE Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema)
Official Title  ICMJE A Phase 2a, Multi-site, Randomized, Double-blind, Vehicle-controlled, Parallel-group Study Of The Pilot Efficacy, Safety, Tolerability, And Pharmacokinetics Of 2% Tofacitinib Ointment In Subjects With Mild To Moderate Atopic Dermatitis
Brief Summary The study is being conducted to evaluate the efficacy, safety and tolerability of 2% tofacitinib ointment (20 mg/g) BID (twice daily) in subjects with mild to moderate atopic dermatitis compared to placebo (vehicle) BID for 4 weeks.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Dermatitis, Atopic
Intervention  ICMJE
  • Drug: Tofacitinib ointment 20mg/g
    Tofacitinib ointment 20mg/g twice daily (BID) for 4 weeks
  • Drug: Placebo ointment (Vehicle)
    Placebo ointment (vehicle) twice daily (BID) for 4 weeks
Study Arms  ICMJE
  • Experimental: Treatment group A
    Intervention: Drug: Tofacitinib ointment 20mg/g
  • Placebo Comparator: Treatment B
    Intervention: Drug: Placebo ointment (Vehicle)
Publications * Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: September 17, 2014) 		69
Original Estimated Enrollment  ICMJE
 (submitted: November 27, 2013) 		70
Actual Study Completion Date  ICMJE September 2014
Actual Primary Completion Date September 2014   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Have a clinical diagnosis of atopic dermatitis (also known as atopic eczema) for at least 6 months prior to Day 1 that has been clinically stable for at least 1 month prior to Day 1 and is confirmed to be atopic dermatitis according to the criteria of Hanifin and Rajka.
  • Have a PGA score of 2 (mild) or 3 (moderate) at Day 1.
  • Have atopic dermatitis on the head (including face, but excluding hair bearing scalp), neck, trunk (excluding groin and genitals), or limbs including palms and soles covering at least 2% of total body surface area (BSA) and up to and including 20% of total BSA at Day 1. At least 2% of the total BSA will need to be on the head (including face, but excluding hair bearing scalp), neck, trunk (excluding groin and genitals), or limbs (excluding palms and soles).

Exclusion Criteria:

  • Evidence of certain skin conditions/infections at baseline
  • Currently have atopic dermatitis on groin, genitals, palm or soles
  • Have certain laboratory abnormalities at baseline
  • Females who are pregnant, breastfeeding, or are of childbearing potential not using highly effective contraception
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 60 Years   (Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02001181
Other Study ID Numbers  ICMJE A3921214
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Pfizer CT.gov Call Center Pfizer
PRS Account Pfizer
Verification Date September 2015

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now